Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Pancreatic Cancer | Research

Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance

Authors: Emily R. Gordon, Carter A. Wright, Mikayla James, Sara J. Cooper

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers based on five-year survival rates. Genes contributing to chemoresistance represent novel therapeutic targets that can improve treatment response. Increased expression of ANGPTL4 in tumors correlates with poor outcomes in pancreatic cancer.

Methods

We used statistical analysis of publicly available gene expression data (TCGA-PAAD) to test whether expression of ANGPTL4 and its downstream targets, ITGB4 and APOL1, were correlated with patient survival. We measured the impact of ANGPTL4 overexpression in a common pancreatic cancer cell line, MIA PaCa-2 cells, using CRISPRa for overexpression and DsiRNA for knockdown. We characterized global gene expression changes associated with high levels of ANGPTL4 and response to gemcitabine treatment using RNA-sequencing. Gemcitabine dose response curves were calculated on modified cell lines by measuring cell viability with CellTiter-Glo (Promega). Impacts on cell migration were measured using a time course scratch assay.

Results

We show that ANGPTL4 overexpression leads to in vitro resistance to gemcitabine and reduced survival times in patients. Overexpression of ANGPTL4 induces transcriptional signatures of tumor invasion and metastasis, proliferation and differentiation, and inhibition of apoptosis. Analyses revealed an overlapping signature of genes associated with both ANGPTL4 activation and gemcitabine response. Increased expression of the genes in this signature in patient PDAC tissues was significantly associated with shorter patient survival. We identified 42 genes that were both co-regulated with ANGPTL4 and were responsive to gemcitabine treatment. ITGB4 and APOL1 were among these genes. Knockdown of either of these genes in cell lines overexpressing ANGPTL4 reversed the observed gemcitabine resistance and inhibited cellular migration associated with epithelial to mesenchymal transition (EMT) and ANGPTL4 overexpression.

Conclusions

These data suggest that ANGPTL4 promotes EMT and regulates the genes APOL1 and ITGB4. Importantly, we show that inhibition of both targets reverses chemoresistance and decreases migratory potential. Our findings have revealed a novel pathway regulating tumor response to treatment and suggest relevant therapeutic targets in pancreatic cancer.

Available only for authorised users

U.S. Mortality Data 1969–2019 when Using SEER*Stat: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969–2019) [Internet]. 2021. Available from: http://www.cdc.gov/nchs.

Sturm N, Ettrich TJ, Perkhofer L. The impact of biomarkers in pancreatic ductal adenocarcinoma on diagnosis, Surveillance and Therapy. Cancers. 2022;14(1):217. https://doi.org/10.3390/cancers14010217.CrossRefPubMedPubMedCentral

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. ; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. doi: https://doi.org/10.1056/NEJMoa1011923. PMID: 21561347.

American Cancer Society. Cancer Facts & Fig. 2022. Atlanta; 2022.

Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, et al. Olaparib Monotherapy for previously treated pancreatic Cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 Nonrandomized clinical trials. JAMA Oncol. 2021;7:693–9.CrossRefPubMedPubMedCentral

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials Group. J Clin Oncol American Society of Clinical Oncology. 2007;25:1960–6.CrossRef

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, et al. Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin Cancer Res American Association for Cancer Research Inc. 2018;24:5018–27.CrossRef

Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, et al. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 2016;10:1169–82.CrossRefPubMedPubMedCentral

Fernández-Hernando C, Suárez Y. ANGPTL4: A multifunctional protein involved in metabolism and vascular homeostasis. Current Opinion in Hematology 2020. page 206–13. Available from: https://doi.org/10.1097/MOH.0000000000000580.

10.

La Paglia L, Listì A, Caruso S, Amodeo V, Passiglia F, Bazan V, et al. Potential role of ANGPTL4 in the Cross talk between metabolism and Cancer through PPAR signaling pathway. PPAR Res. 2017. https://doi.org/10.1155/2017/8187235.CrossRefPubMedPubMedCentral

11.

Lei X, Shi F, Basu D, Huq A, Routhier S, Day R, et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem American Society for Biochemistry and Molecular Biology Inc. 2011;286:15747–56.

12.

Kim SH, Park YY, Kim SW, Lee JS, Wang D, DuBois RN. ANGPTL4 induction by prostaglandin E 2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res. 2011;71:7010–20.CrossRefPubMedPubMedCentral

13.

Tan MJ, Teo Z, Sng MK, Zhu P, Tan NS. Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res. 2012;10(6):677–88. https://doi.org/10.1158/1541-7786.MCR-11-0519.CrossRefPubMed

14.

Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, et al. Angiopoietin-like 4 protein elevates the Prosurvival Intracellular O2-:H2O2 ratio and confers Anoikis Resistance to Tumors. Cancer Cell Cell Press. 2011;19:401–15.CrossRef

15.

Teo Z, Sng MK, Chan JSK, Lim MMK, Li Y, Li L, et al. Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3γ expression. Oncogene. 2017;36:6408–19.CrossRefPubMedPubMedCentral

16.

Zhang K, Zhai Z, Yu S, Tao Y. DNA methylation mediated down-regulation of ANGPTL4 promotes colorectal cancer metastasis by activating the ERK pathway. J Cancer. 2021;12:5473–85.CrossRefPubMedPubMedCentral

17.

Zhao J, Liu J, Wu N, Zhang H, Zhang S, Li L, et al. ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer. Oncol Lett. 2020;20:2499–505.CrossRefPubMedPubMedCentral

18.

Cai YC, Yang H, Wang KF, Chen TH, Jiang WQ, Shi YX. ANGPTL4 overexpression inhibits tumor cell adhesion and migration and predicts favorable prognosis of triple-negative breast cancer. BMC Cancer. 2020;20. https://doi.org/10.1186/s12885-020-07343-w.

19.

Yan HH, Jung KH, Lee JE, Son MK, Fang Z, Park JH, et al. ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis. Cancer Lett. 2021;519:185–98.CrossRefPubMed

20.

Gupta N, Park JE, Tse W, Keem Low J, Kon OL, Mccarthy N, et al. ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer. Oncotarget. 2019;10(5):5870–982. https://www.oncotarget.com/article/27235/text/.

21.

Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12(4):828–63. https://doi.org/10.1038/nprot.2017.016.CrossRefPubMedPubMedCentral

22.

Larson B, Held P, Banks P. Optimization of Perkin Elmer’s AlphaScreen® cAMP assay on the Synergy^™ H4 hybrid Multi-Mode Microplate Reader [Internet]. 2010. http://www.biotek.com.

23.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15. https://doi.org/10.1186/s13059-014-0550-8.

24.

Ge SX, Son EW, Yao R, iDEP. An integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19. https://doi.org/10.1186/s12859-018-2486-6.

25.

Baecker V. ImageJ Macro Tool Sets for Biological Image Analysis. Conference.

26.

Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2020;29:28–35.CrossRefPubMed

27.

Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019;47(D1):D419–26.CrossRefPubMed

28.

Therneau T. A Package for Survival Analysis in R. R package version 3.4-0 [Internet]. 2022. https://CRAN.R-project.org/package=survival.

29.

Kassambara A, Kosinski M, Biecek F. S.Package “survminer” Type Package Title Drawing Survival Curves using “ggplot2;” 2022.

30.

Wickham H. Ggplot2: elegant graphics for data analysis. Springer; 2009.

31.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12). https://doi.org/10.1186/s13059-014-0550-8.

32.

Kolde R. Pretty Heatmaps. R package version 1.0.12 [Internet]. 2019. Available from: https://CRAN.R-project.org/package=pheatmap.

33.

Frank M, Harrell E, Hmisc. A package of miscellaneous R functions [Internet]. 2020. Available from: http://biostat.mc.vanderbilt.edu/Hmisc.

34.

Urbanek S, Johnson K, tiff. Read and Write TIFF Images. R package version 0.1–11. 2020; Available from: https://CRAN.R-project.org/package=tiff.

35.

Jia Y, Xie J. Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes and Diseases. 2015;2(4):299–306. https://doi.org/10.1016/j.gendis.2015.07.003.CrossRefPubMedPubMedCentral

36.

Wei X, Zhou X, Zhao Y, He Y, Weng Z, Xu C. A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients. Sci Rep. 2021;11(6087). https://doi.org/10.1038/s41598-021-85680-x.

37.

Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, et al. Intrinsic chemoresistance to Gemcitabine is Associated with decreased expression of BNIP3 in pancreatic Cancer. Clin Cancer Res. 2005;11(8):3094–101. https://aacrjournals.org/clincancerres/article/11/8/3094/188241/Intrinsic-Chemoresistance-to-Gemcitabine-Is.CrossRefPubMed

38.

Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96:457–63.CrossRefPubMedPubMedCentral

39.

Vasaikar SV, Deshmukh AP, den Hollander P, Addanki S, Kuburich NA, Kudaravalli S, Joseph R, Chang JT, Soundararajan R, Mani SA. EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. Br J Cancer. 2021;124(1):259–69. https://doi.org/10.1038/s41416-020-01178-9. Epub 2020 Dec 10. PMID: 33299129; PMCID: PMC7782839.CrossRefPubMed

40.

Huang L, Jansen L, Balavarca Y, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Primic-Žakelj M, Zadnik V, Besselink MG, Schrotz-King P, Brenner H. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med. 2018 Aug 21;16(1):125. doi: https://doi.org/10.1186/s12916-018-1120-9. PMID: 30126408; PMCID: PMC6102804.

41.

Ghanem NZ, Matter ML, Ramos JW. Regulation of Leukaemia Associated rho GEF (LARG/ARHGEF12). Small GTPases. 2022;13(1):196–204. https://doi.org/10.1080/21541248.2021.1951590.CrossRefPubMed

42.

Lin J, Xu Z, Xie J, Deng X, Jiang L, Chen H, Peng C, Li H, Zhang J, Shen B. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Cell Death Dis. 2021;12(8). https://doi.org/10.1038/s41419-021-03985-1.

43.

Cruz-Monserrate Z, Qiu S, Evers BM, O’Connor KL. Upregulation and redistribution of integrin α6β4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol. 2007;20:656–67.CrossRefPubMedPubMedCentral

44.

Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O’Connor PM, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem. 1997;272:25576–82.CrossRefPubMed

45.

Cho S, Lu M, He X, Ee PLR, Bhat U, Schneider E, et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci. 2011;108:20778–83.CrossRefPubMedPubMedCentral

46.

Sangphech N, Keawvilai P, Palaga T. Notch signaling increases PPARγ protein stability and enhances lipid uptake through AKT in IL-4-stimulated THP-1 and primary human macrophages. FEBS Open Bio. 2020;10:1082–95.CrossRefPubMedPubMedCentral

47.

Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A et al. A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. iScience 2020;23. https://doi.org/10.1016/j.isci.2020.101496.

48.

Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, et al. β4 integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 2013;123:682–99.PubMedPubMedCentral

49.

Masugi Y, Yamazaki K, Emoto K, Effendi K, Tsujikawa H, Kitago M, Itano O, Kitagawa Y, Sakamoto M. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Lab Invest; 2015;95(3):308 – 19. doi: https://doi.org/10.1038/labinvest.2014.166. PMID: 25599535.

50.

Giancotti FG, Ruoslahti E. Integrin signaling. Science. 2017;285:1028–32.CrossRef

51.

Meng X, Liu P, Wu Y, Liu X, Huang Y, Yu B, et al. Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1/2 signaling pathway. Bosn J Basic Med Sci. 2020;20:106–16.PubMedPubMedCentral

Title: Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance
Authors: Emily R. Gordon
Carter A. Wright
Mikayla James
Sara J. Cooper
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11010-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Comparative efficacy of different combinations of acapella, active cycle of breathing technique, and external diaphragmatic pacing in perioperative patients with lung cancer: a randomised controlled trial

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey

Protocol for the SEHNeCa randomised clinical trial assesing Supervised Exercise for Head and Neck Cancer patients

Nomogram for predicting lymph node metastasis in patients with ovarian cancer using ultrasonography: a multicenter retrospective study

Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer